Targeting of Ykl-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding.

IF 3.8 4区医学 Q2 GENETICS & HEREDITY

Current gene therapy Pub Date : 2025-02-19 DOI:10.2174/0115665232332419250213081510

Hebatallah Ahmed Mohamed Moustafa, Ahmed Umer Sohaib, Iqra Saleem, Asmat Ullah

{"title":"Targeting of Ykl-40 as a Protumor in Personalized Medicine: A New Dimension in Disease Understanding.","authors":"Hebatallah Ahmed Mohamed Moustafa, Ahmed Umer Sohaib, Iqra Saleem, Asmat Ullah","doi":"10.2174/0115665232332419250213081510","DOIUrl":null,"url":null,"abstract":"Background: Individualization of the therapeutic plan for cancer patients is the essence of modern clinical practice. Standard cancer diagnostic and prognostic factors are invasive, and their value for the stratification of cancer patients with a higher risk of local or distant recurrence is limited. YKL-40 is a protumor glycoprotein linked to the immunosuppressive tumor in a microenvironment and an important biomarker of cell activation, proliferation, and migration.Objective: The objective is to update the review, and molecular and clinical research should investigate novel modalities of targeting this glycoprotein for cancer treatment.Methodology: Relevant studies published in the English language were identified by searching PubMed, Google Scholar, and MEDLINE from January 2000 to December 2023. Published studies that specifically elicited the role of YKL-40 as a biomarker in different types of tumors were included.Results: YKL-40 cancer prognostic effect was reported in various cancer types.Conclusion: Since antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232332419250213081510","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Individualization of the therapeutic plan for cancer patients is the essence of modern clinical practice. Standard cancer diagnostic and prognostic factors are invasive, and their value for the stratification of cancer patients with a higher risk of local or distant recurrence is limited. YKL-40 is a protumor glycoprotein linked to the immunosuppressive tumor in a microenvironment and an important biomarker of cell activation, proliferation, and migration.

Objective: The objective is to update the review, and molecular and clinical research should investigate novel modalities of targeting this glycoprotein for cancer treatment.

Methodology: Relevant studies published in the English language were identified by searching PubMed, Google Scholar, and MEDLINE from January 2000 to December 2023. Published studies that specifically elicited the role of YKL-40 as a biomarker in different types of tumors were included.

Results: YKL-40 cancer prognostic effect was reported in various cancer types.

Conclusion: Since antibodies against YKL-40 can inhibit tumor angiogenesis and cancer progression, it can be suggested as an attractive candidate for chemical cancer therapy and immunomodulation.

查看原文本刊更多论文

个性化医疗中Ykl-40作为肿瘤的靶向：疾病认识的新维度。

背景：癌症患者治疗方案的个体化是现代临床实践的本质。标准的癌症诊断和预后因素具有侵袭性，其对局部或远处复发风险较高的癌症患者分层的价值有限。YKL-40是微环境中与免疫抑制肿瘤相关的一种肿瘤糖蛋白，是细胞活化、增殖和迁移的重要生物标志物。目的：目的是更新综述，分子和临床研究应该探索靶向这种糖蛋白治疗癌症的新模式。方法：检索2000年1月至2023年12月PubMed、谷歌Scholar和MEDLINE的相关英文研究。已发表的研究明确揭示了YKL-40作为生物标志物在不同类型肿瘤中的作用。结果：YKL-40在不同类型肿瘤中均有预后作用。结论：YKL-40抗体具有抑制肿瘤血管生成和肿瘤进展的作用，可作为肿瘤化学治疗和免疫调节的重要候选药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current gene therapy 医学-遗传学

CiteScore

6.70

自引率

2.80%

发文量

期刊介绍： Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.